Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the ...
Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.
Sclerosteosis arises from mutations in the SOST gene, causing abnormally high bone mass and skeletal overgrowth, which can lead to severe health issues such as hearing loss and increased intracranial ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...
Eluciderm Inc. has identified compounds acting as inhibitors of Wnt signaling and/or poly(ADP-ribose) polymerase tankyrase-2 (TNKS2; PARP5B) and/or poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and/or ...
Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.
Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that ...
BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results